Immunic, inc. (VTL)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Cash flows from operating activities:
Net loss

-39,107

-34,933

-32,054

-25,636

-1,467

-11,542

-21,318

-32,002

-53,864

-52,078

-49,224

-46,921

-43,982

-40,969

-39,094

-41,216

-46,854

-52,023

-56,119

-56,616

-51,677

-47,667

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

59

50

43

37

-204

15

228

441

887

998

1,184

1,388

1,649

1,808

1,785

1,690

1,528

1,328

1,181

1,166

1,084

1,087

1,084

1,005

933

799

0

0

0

Other

-

-

-

-

-

-

-

-

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Revaluation of preferred stock warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Revaluation of future purchase rights liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,600

2,614

4,806

4,256

-1,306

0

0

0

Stock-based compensation

6,865

6,512

6,182

5,983

-1,553

0

1,837

3,061

5,770

5,480

4,930

5,090

4,943

4,678

4,477

4,235

4,224

4,029

3,688

3,203

2,878

2,510

2,122

1,757

1,278

948

0

0

0

Contingent payment settled in common stock

-

-

-

-

-

-

-

-

345

256

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

Changes in operating assets and liabilities:
Other current assets and prepaid expenses

4,144

2,224

3,578

1,941

103

-218

-628

-1,019

-550

-165

213

311

566

232

-343

-586

1

-143

-341

427

-522

-279

546

902

1,006

1,141

0

0

0

Accounts payable

-555

-462

1,923

-752

465

1,200

271

770

-254

287

-128

-53

298

-459

558

-17

-191

281

-209

-353

215

46

-482

20

-232

-91

0

0

0

Accrued expenses

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

669

1,102

174

-1,415

407

1

1,951

2,941

4,016

4,490

3,815

2,712

922

-587

-3,912

-5,256

-4,980

-3,584

193

2,719

3,352

5,396

3,668

3,625

3,983

2,266

0

0

0

Accrued expenses and other liabilities

-

-

-

-

-

-

-

-

-8

6

-31

-43

-75

-98

-120

-133

-128

-126

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

0

-36,728

-

-35,963

-40,112

-46,402

-49,952

-51,054

-50,206

-44,967

-40,825

-40,567

-37,481

-33,457

-28,648

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

52

55

50

42

-111

32

123

287

561

685

693

796

705

556

485

525

1,791

2,340

2,336

2,344

1,274

1,409

1,672

1,971

2,173

1,484

0

0

0

Purchases of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,999

0

0

0

Sales of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17,000

0

0

0

Cash distribution in connection with ELAD Assets sale

-

-

-

-

-

-

-

-

-

-

-

-

-

-533

-1,051

-1,178

-1,213

-1,059

-384

185

528

631

710

593

689

608

0

0

0

Proceeds from sale of equipment

-

-

-

-

-

0

0

0

4

7

7

7

3

2

2

2

2

0

0

0

0

-

-

-

-

-

-

-

0

Net cash used in investing activities

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

0

-382

-

568

655

-576

-1,281

-1,952

-2,529

-1,802

-2,040

-2,382

2,437

7,140

11,909

0

0

0

Cash flows from financing activities:
Proceeds from issuance of common stock in pre-closing financing, net of issuance costs of $61

-

-

-

-

-

-

-

-

-

5

1

1

1

32

273

361

408

515

0

0

0

-

-

-

-

135

0

0

0

Deferred financing costs

-

-

-

-

-

-

-

-

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from public offering of common stock, net of issuance costs of $37

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Principal payments on term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of preferred stock

-

-

-

-

-

-

-

-

-

37,998

38,635

41,211

45,855

12,355

0

0

0

-

-

0

0

-

-

-

-

-

-

-

0

Proceeds from stock subscription not yet issued

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

18,167

37,265

37,265

69,051

53,195

0

0

0

Proceeds from debt, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

Net cash provided by financing activities

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from early exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

227

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

0

45,873

-

43,734

41,121

36,609

32,421

33,676

33,840

88,984

106,918

90,883

89,445

66,207

50,445

0

0

0

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-655

-589

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash

-9,441

16,297

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Valuation of future purchase rights upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,294

0

0

0

Beneficial conversion underlying the senior preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,410

6,581

8,628

8,381

6,303

0

0

0

Amortization of deemed dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,744

0

0

0

-

-

-

-

Stock issuance costs included in liabilities

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment included in liabilities

-

-

-

-

-

-

-

-

-64

16

-30

135

128

41

72

-19

-925

9

300

47

1,109

277

21

101

261

170

0

0

0

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

156

-495

730

394

0

0

0

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Supplemental disclosure of noncash investing and financing activities:
Leased assets obtained in exchange for operating lease liabilities

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of assets through debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of Series D warrant in connection with Series D redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Conversion of debt for redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Conversion of convertible preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Purchase of property and equipment included in accounts payable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reconciliation of cash, cash equivalents and restricted cash:
Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-4

-5

-12

-12

-10

-7

1

1

-1

-1

0

-1

3

0

0

0

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-42,989

-3,090

-1,697

2,555

8,760

-23,425

8,334

1,652

-10,381

-18,822

-19,337

-18,894

42,216

64,052

47,933

54,401

39,889

33,709

0

0

0

Leasehold improvements paid for by landlord

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in stock option early exercise repurchase liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

104

104

0

0

0

-

-

-

-

Change in stock option early exercise repurchase liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-